A heralded global leader with a 15-year track record in strategy development that delivers sector impact and business results, Ajay has a strong foundation in management, pharmaceutical manufacturing operations and cGMP systems with a broad understanding of business finance, P&L and lean concepts. With a ubiquitous need to never stop learning and a penchant for creative problem solving, he plans to ensure that CiplaQCIL meets the needs of its various stakeholders. The immediate priority of the business is to make it profitable, followed by a focus on sustainable and profitable growth, and to improve business agility. “I see a future of growth, where we can make a positive impact in people’s lives, all made possible by a team that are deeply driven and rooted in a culture of excellence, accountability, innovation and integrity.”

Ajay believes that the future for CiplaQCIL is becoming an agile brand which responds to change with great speed, thereby bringing solutions to Africa’s biggest disease burdens. “We will work hard to deliver value for our various stakeholders – staff, shareholders, consumers, healthcare professionals, and partners like governments.”Ajay holds a Master of Business Administration in Management and Leadership from Nelson Mandela University - South Africa and a Bachelor of Pharmacy from the Rajiv Gandhi University of Health Sciences (RGUHS) - India. He’s also received enterprise leadership training from the Cipla Leadership Ascent Program and a certificate in dIgital tech value creation from INSEAD Singapore.

He’s been on the frontline of implementing operational strategies that drive revenue growth and profitability. Outside of work, his greatest achievements have been completing a cycling event of 109km and a 10km obstacle course. He believes sport is a good way to train determination and resilience.

Mr Katongole is also the Founder of Vero Food Industries – a food and beverage company; an independent Non-Executive Director of Barclays Bank (U) Ltd; Chairman of the Uganda National Oil Company and Chairman of the Advisory Board of London based TLG Capital Ltd. He is a member of the Initiative for Global Development (Frontier 100) – a prestigious group that joins the most successful business leaders operating in frontier markets.

In addition to numerous nominations, Mr Katongole has won several business awards. He was the East African Winner and representative at the 2013 Ernst and Young World Entrepreneur of the Year Awards in Monte Carlo, bagged the 2012 Africa Business Leadership Award and the 2012 Africa Entrepreneurship Award.

He is a Rotarian who has steadily and diligently served as District Governor for Rotary District 9211 which comprises of Tanzania and Uganda and currently serves as Endowment and Major Gifts Advisor for Africa. He is a multiple Major Donor to the Rotary Foundation.
Mr Katongole holds a Master of Arts Degree in Economic Policy and Planning and
an Honours Bachelor of Statistics degree, both from Makerere University.

He was based in China from July 2005, where he held the position of Marketing Director for AstraZeneca in China. He successfully built and launched brands that were market leaders in China in the areas of cardiovascular, gastrointestinal, respiratory and anaesthesia.

Prior to this assignment, he spent four and half years within global oncology marketing based in the UK, first as a Strategy and Portfolio Manager and then as Global Brand Manager. This global experience allowed him to lead and deliver several innovative and novel programmes to support the US, Asian and European market launches.

She has worked for branded and generic companies such as Watson/Actavis, Endo/ Dupont Pharmaceuticals, Zenith Goldline and Thames Pharmacol, with extensive experience in dealing with regulatory bodies such as the Food and Drug Administration (FDA), the Medicines and Healthcare products Regulatory Agency, the Brazilian Health Regulatory Agency (ANVISA) and the Medicines Control Council (MCC).

Dr Ranjana served in the role of senior Vice President of Global Quality for Watson/ Actavis Pharmaceuticals, and was responsible for their quality control globally. Prior to Watson/Actavis, she worked as Vice President of Quality and Compliance at Endo Pharmaceuticals where she had the privilege of creating commercial Research & Development and Quality Assurance department. Products ranged from solids (mainly narcotics), patches, suppositories, and devices. She was actively involved in the pre-clinical and phase1 through phase 3 trials.

Dr Ranjana has a Doctorate in Health Administration from the University of Phoenix, an MBA from Dowling College, and a Bachelor’s of Science (Honours) in Chemistry from Mithibai College of Arts and Chauhan Institute of Science, Mumbai. She has a Postgraduate Diploma in Pharmaceutical and Chemical Analysis from Sophia College and has undertaken a Leadership course in Pharmaceutical and Biologics from Harvard University.

She has published learned articles and lectured in many pharmaceutical courses and seminars on various topics (such as validation, quality approvals and compliance issues). Dr Ranjana was awarded the Rising Star award in 2006 by the Healthcare Business Association.

Mr Daly is a chartered accountant and holds a B. Com Honours degree in accounting from the University of Natal, Pietermaritzburg. He previously held managerial roles in the corporate finance and auditing departments of one the big account firms in South Africa and has also worked abroad in London and Mozambique.

Prof Mugyenyi has been a principal investigator on dozens of landmark research projects, funded by organisations such as the National Institutes of Health (NIH), European Union, World Health Organisation (WHO) and the Medical Research Council (MRC). His research and publications cover a wide spectrum of HIV/AIDS-related diseases and other medical conditions. Specific areas of his research include paediatric and adult HIV treatment, drug trials, HIV resistance, HIV prevention, immunological studies including HIV vaccine trials, pharmacokinetic, molecular and epidemiological studies as well as social and economic impact of HIV.

Internationally, he has served as a board member of several institutions and organizations in Africa, UK, India and the USA. Other roles include membership of various advisory boards including HIV Vaccine Trials Network, USA, Massachusetts General Hospital and Institute of Medicine of the National Academies, USA and the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 initiative to end the HIV epidemic, among others.

Mr Baliddawa has extensive experience in management and leadership roles, specifically in country management, formulating and monitoring the implementation of PWC’s strategic growth plan for Africa, risk, quality and compliance standards management and firm wide financial management and reporting.

Mr Baliddawa is a Ugandan national and is currently President of the Institute of Corporate Governance of Uganda, Chair of the Audit Committees of the Commercial Bank of Africa, Alliance Africa General Insurance Limited and New Vision Group, and a Board member of all three organizations. He is Chair of the Uganda-Norway Friendship Association, a Member of the Council of Uganda Martyrs University and Chair of its Audit Committee.

He has received awards from the World Bank, national and international accountancy organizations and Lions Club International. He undertook his professional education at the London School of Accountancy obtaining membership of the Association of Chartered Certified Accountants (ACCA).

She is a pillar of Research and Development (R&D) at Cipla and has spearheaded use of cutting-edge technology platforms, equipment, drug-device combinations, and targeted drug delivery dosage forms to fulfil unmet patient needs. She has to her credit, several patents in the areas of formulation development and technology in solid oral dosage forms, topical delivery systems and inhalation medical devices. She has provided technical leadership to multi-disciplinary R&D teams within a cross-functional environment to build and deliver a high throughput R&D with technology being the core focus. She completed her Bachelor’s in Pharmacy in 1985 in Mumbai and received her Executive MBA degree from Washington University, St. Louis in 2017.

She is a recipient of the Eminent Researcher Award by the Indian Pharmaceutical Association in 2007 and FDD Express Pharma Award for Outstanding Achievement in Formulation Development and Drug Delivery in 2017. She has also been honoured with the Indian Glory Award in 2017 by Indian Friendship Society and the Bharat Ratna Dr. APJ Abdul Kalam Excellence Award in 2018 for outstanding and distinguished services to the nation.

He holds a Master’s degree in Business Administration from the Edinburgh Business School - Herriot Watt University, a Postgraduate Diploma in Business Administration from the University of Leicester and, a Postgraduate Diploma in Business Management from the Uganda Management Institute. He has undertaken Executive Management Training at the Strathmore Business School, The Wharton School (University of Pennsylvania) and the Gordon Institute of Business (University of Pretoria). He is a Balanced Score Card Professional (George Washington University of Professional Studies). He has also undertaken various short courses in leadership, risk management, financial management, performance management and corporate governance.

Previously, he worked as the Head of Sales and Operations at NSSF and the Head of Commercial Division at Bank of Africa-Uganda Ltd, where he had also previously worked as the Chief Accountant and the Head of Internal Controls. He is a strategic leader responsible for providing direction and managing performance. He is known for being a changemaker with a history of structuring processes and building strong and motivated high-performance teams.
He is currently the Chairperson of the Board Audit Committee at the Entrepreneurs Financial Centre (EFC) and has served on the Board of Kampala Club Limited. He is also a member of the Rotary Club of Kampala North.